United States: Complicated Landscape Awaits New FDA Commissioner

Last Updated: May 16 2017
Article by Ethan Jorgensen-Earp

Ethan-Jorgensen-Earp is a Public Affairs Advisor in our Washington D.C. office.


  • Dr. Scott Gottlieb's confirmation as Commissioner of Food and Drugs marks an opportunity for Congress and the public to determine whether he will be able to break the status quo at the U.S. Food and Drug Administration (FDA) or merely uphold it.
  • Several near-term issues will affect FDA operations, staffing and other resources, potentially putting the agency chief in the position of having to educate – and sometimes buck – the White House if he is to pursue an agenda of change.
  • A principal question for those involved in drug and device development will be how Gottlieb and the leadership team at the FDA, under increasingly limited financial and workforce resources, will respond to the desire by lawmakers, the Trump Administration and the public for new and faster medical advancements while keeping costs low.

A poet from West London once wrote, "Meet the new boss, same as the old boss," a frustrated statement lamenting that the status quo in any system tends to prevail despite calls for revolution. If one judges the potential for change at the U.S. Food and Drug Administration (FDA) based on its highest leadership, Dr. Scott Gottlieb's confirmation on May 9, 2017, as Commissioner of Food and Drugs marks an opportunity for Congress and the public to determine whether he will be able to break the status quo or merely uphold it.

Gottlieb's Background the New Normal?

In terms of experience, Gottlieb would appear to be a status quo choice. Gottlieb is a board certified physician in internal medicine and has significant past experience in the federal government, most notably serving as FDA Deputy Commissioner for Medical and Scientific Affairs. His time working with the FDA, the Centers for Medicare & Medicaid Services (CMS), and other federal agencies has given him extensive experience with a diverse set of healthcare issues, including global health, health IT and biodefense. It was similar government service that made former President Barack Obama's first choice for the FDA lead, Dr. Margaret Hamburg – also an internal medicine physician – a natural one. She was confirmed unanimously by the U.S. Senate in 2009.

In addition, Gottlieb has spent several years consulting for numerous organizations in the biotech industry and has served on the boards of a handful of such companies, including Gradalis and Tolero Pharmaceuticals. He has also served as a partner at New Enterprise Associates, a venture capital firm that has advised or invested in dozens of healthcare entities and biotech companies, including GlaxoSmithKline and Vertex Pharmaceuticals. Although traditionally a source of concern among lawmakers, Gottlieb's involvement with industry may now be considered closer to the norm as Gottlieb's immediate predecessor, Duke University cardiologist Dr. Robert Califf was also involved with industry, gaining support from numerous entities to finance the clinical research center he founded at Duke. Both Hamburg and Califf have publicly endorsed Gottlieb for the post.

While Gottlieb's selection extends a nascent pattern of industry expertise in the agency's top office, what differentiates his confirmation are the political circumstances surrounding it. His confirmation hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee and subsequent vote, which represent the first two hurdles to confirmation as FDA chief, were on the whole uneventful, especially given his self-imposed, year-long moratorium on personal involvement in agency decisions with respect to more than 20 companies to which he's had financial or advisory ties. However, it was plain to those watching, and those who have followed actions by the Trump Administration in recent months, that Gottlieb and his staff will have to be mindful of several issues in the near-term. Two of those – funding and politics – will affect operations, staffing and other resources at the agency, and potentially put the agency chief in the position of having to educate – and sometimes buck – the White House if he is to pursue an agenda of change at the FDA.

Funding a Key Challenge

To get a sense of how difficult it is to generate consistent non-defense discretionary funding for agencies like the FDA, one need look only at the National Institutes of Health (NIH). Over the past two decades, the NIH has garnered strong bipartisan support in Congress and throughout multiple presidential administrations, leading to calls for increased funding and resources for the agency to fulfill its research and public health agenda. Despite such popularity, following its doubling in funding from $13.6 billion to $27.1 billion in the early 2000s, the NIH has seen only modest increases in its overall budget, which now stands at approximately $34 billion. And, even with baseline funding increases, purchasing power at the NIH has dropped by more than 20 percent since 2003, as discretionary funding has been unable to keep pace with biomedical research inflation.

The game is even tougher for the FDA, as funding for the agency tends to take a backseat in Congress and, to a certain extent, with the public. This is because, in part, FDA funding is split between discretionary funding and user fees, which are carefully negotiated between industry and the agency to fund the review of new products and other activities. However, these fees, which made up 42 percent of FDA's overall funding in Fiscal Year (FY) 2016, are very limited in scope, leaving less than $3 billion of discretionary funding to run the remaining operations of an agency that has nearly 17,000 employees and whose regulated industries account for more than a quarter of total U.S. consumer spending.

The 21st Century Cures Act, which was signed into law at the end of last Congress, promised to deliver new provisions affecting or establishing policies and programs at the NIH, FDA, and the Health Resources and Services Administration (HRSA), among other agencies, as well as a much needed funding boost for these agencies to implement the law. Indeed, the legislation included $4.8 billion over 10 years for the NIH outside of the regular appropriations process for major projects, including the Precision Medicine Initiative and the BRAIN Initiative. However, while this funding increase served as a strong congressional endorsement of the NIH's mission, little can be made of the mere $500 million over 10 years granted by the bill to the FDA. This small sum must supplement numerous provisions in the law to accelerate and expand the FDA's review work, including advancing therapies for rare diseases, expanding the patient voice in drug development and accelerating approval pathways for regenerative medicine therapies, among many others. This same sentiment was echoed in the recently passed FY 2017 appropriations bill, in which the NIH saw an increase of $2 billion to the FDA's $39 million. In sum, Gottlieb and team must do more with less – and not in a political vacuum.

A Look Ahead

Many recent discussions have focused on both accelerating FDA drug and device reviews to get patients new therapies as quickly as possible and escalating drug prices, especially following recent investigations into the pricing practices of several pharmaceutical companies. As many remember, President Donald Trump was critical of the FDA's drug approval process in his February speech to a joint session of Congress, calling the process "slow and burdensome" and saying that it prevented therapies from getting to the patients who need them. While the speech, held on Rare Disease Day, did elevate an important message about the development of therapies for the rare disease population, median approval times for both new drug applications and biologics license applications have actually quickened over the past five years, from 10.8 months to 10.1, a vast improvement over the 26.9 months it took in 1993. This same trend also applies to medical devices, which now take about eight months for approval rather than more than a year in 2010. Compared with the European Medicines Agency (EMA), the FDA's review times are about two months faster despite approving 26 more products than the EMA during the same time period.

Regardless of those improvements, the Trump Administration has committed itself, and especially FDA leadership, to be even more efficient and effective by "doubling" the total amount of industry funding collected from the aforementioned user fees to more than $2 billion in the administration's FY 2018 budget blueprint, presumably to give more resources to FDA's review divisions. However, the FDA currently takes in just shy of $1.4 billion annualized in user fees in FY 2017 – assuming that "medical products" include prescriptions, generics, biosimilars and medical devices – and the FY 2018 user fee amounts have already been negotiated between the FDA and industry. Given that the FY 2018 base fee amounts already grant at least $430 million over FY 2017, excluding workload and inflation adjustments, the administration's proposal could strain industry relationships by calling for a renegotiation to the user fee amounts while yielding very little for the agency in terms of added financial resources. Thus, while a call for increased FDA funding could be a deeper signal of confidence in Gottlieb's ability to create a balance between the administration and industry, he will certainly be preoccupied with running an agency that currently has more than 1,000 job vacancies and is still subject to an administration-ordered hiring freeze that, unless completely lifted, will continue to affect the FDA's ability to hire senior-level experts.

As for drug prices, President Trump had made their reduction a notable campaign promise. Since taking office, he has found basic alignment on the issue with several unlikely individuals in Congress on the opposite end of the political spectrum, including Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.). Although there have been conversations between drug pricing hawks on both sides of the aisle, no precise agreements have been arranged. Gottlieb has already toed the line in his confirmation hearing by supporting unspecified mechanisms to increase competition in the pharmaceutical market to drive down costs. However, the FDA remains a public health agency that is statutorily limited to reviewing and approving new therapies, not negotiating and setting their prices. And although Gottlieb's views on the issue could create a new environment for conversations between the agency and industry concerning drug prices, any changes will most likely happen over the long term through larger changes in healthcare reimbursements.

A principal question for those involved in drug and device development will be how Gottlieb and the leadership team at the FDA, under increasingly limited financial and workforce resources, will respond to the desire by lawmakers, the administration and the public for new and faster medical advancements while keeping costs low. At this point, one can only begin to speculate at the progress of innovation during Gottlieb's tenure. However, it seems likely that change will be slower – and the status quo more persistent – than many predicted at the beginning of the 45th presidency.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions